Table 5. Association between the change in HRQoL and clinical characteristics at the 6-month follow-up and the 12-month follow-up.

	ΔSGRQ total		ΔSGRQ symptom		ΔSGRQ activity		ΔSGRQ impact
	6-month follow-up	12-month follow-up	6-month follow-up	12-month follow-up	6-month follow-up	12-month follow-up	6-month follow-up	12-month follow-up
ΔFVC% predicted	-0.481***	-0.412***	-0.059	-0.223*	-0.551***	-0.484***	-0.377***	-0.318**
ΔDLco% predicted	-0.458***	-0.554***	0.013	-0.253*	-0.559***	-0.553***	-0.355**	-0.514***
ΔmMRC	0.641***	0.706***	0.082	0.399***	0.692***	0.755***	0.537***	0.578***
ΔLCQ	-0.562***	-0.584***	-0.239**	-0.420***	-0.404***	-0.411***	-0.559***	-0.595***

Data are presented as the beta estimates of regression coefficients. At the 6-month follow-up, 81 patients completed the pulmonary function assessment, although ΔDLco% predicted data were not available for 4 patients. A total of 147 patients completed the LCQ assessment, and 146 patients completed the mMRC assessment. All data were available. At the 12-month follow-up, 79 patients completed the pulmonary function assessment, although ΔDLco% predicted data were not available for 6 patients. A total of 140 patients completed the mMRC and LCQ assessments, and all data were available. FVC, forced vital capacity; ΔFVC% predicted, FVC change from baseline at 6-month follow-up; DLco, diffusing capacity of the lung for carbon monoxide; ΔDLco % predicted, DLco change from baseline at the 6-month follow-up; mMRC, modified Medical Research Council dyspnea scale; ΔmMRC, mMRC change from baseline at the 6-month follow-up; LCQ, Leicester Cough Questionnaire; ΔLCQ, LCQ change from baseline at the 6-month follow-up.

* P≤0.05,

** P≤0.01,

*** P≤0.001